Clinical trials: Glomerulosclerosis, Focal
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Nephrosis, Focal Lipoid Glomerulosclerosis
Steroid Treatment for Kidney Disease
Focal segmental glomerulosclerosis (FSGS) and minimal change disease are kidney diseases that are associated with increased excretion of protein in the urine.
- Trial name
- NCT00065611
- Testing
- Oral dexamethasone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental
Podocyte Retinoids
This is a pilot study of retinoids for patients with unsatisfactory response to conventional treatment of nephrotic syndrome due to focal segmental glomerulosclerosis or minimal change disease, two renal disorders associated with…
- Trial name
- NCT00098020
- Testing
- Isotretinoin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Fibrosis, Focal Glomerulosclerosis
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
This study will examine the effectiveness of the drug pirfenidone in treating focal segmental glomerulosclerosis (FSGS). Patients with this disease have kidney fibrosis (scarring) and proteinuria (excessive excretion of protein…
- Conditions
- Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome
- Trial name
- NCT00001959
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Diseases
Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
FSGS is an immunologic disorder wherein circulating immune proteins cause damage to the kidneys and progressive injury and scarring.
- Trial name
- NCT01155141
- Testing
- H.P. Acthar Gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stanford University
Glomerulosclerosis, Focal Segmental
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
This is a single-arm, multicenter, open-label Phase II, proof-of-mechanism study to evaluate the efficacy, safety, tolerability and pharmacokinetics of losmapimod in approximately 21 subjects with primary (idiopathic) focal…
- Trial name
- NCT02000440
- Testing
- Losmapimod
- Where
- 12 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Focal Segmental Glomerulosclerosis
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome
- Trial name
- NCT03703908
- Testing
- CCX140-B
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Amgen
Idiopathic Focal Segmental Glomerulosclerosis
Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Focal segmental glomerulosclerosis (FSGS) is a condition that harms the kidney "filters" that remove waste from the blood. Proteins are supposed to stay in the blood. Damaged "filters" let protein get into the kidney.
- Trial name
- PODOCYTE (NCT02633046)
- Testing
- Acthar Gel
- Where
- 47 sites in United States, Argentina and 5 more
- Volunteers
- 63 people
- Sponsor
- Mallinckrodt ARD LLC
FSGS, Focal Segmental Glomerulosclerosis
A Study of CCX140-B in Subjects With FSGS
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia
- Conditions
- FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
- Trial name
- NCT03536754
- Testing
- CCX140-B
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 46 people
- Sponsor
- Amgen
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal…
- Conditions
- Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT02592798
- Testing
- Abatacept, Normal Saline, D5W
- Where
- 27 sites in United States
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
FSGS
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
- Trial name
- NCT02683889
- Testing
- Acthar
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Colorado, Denver
Focal Segmental Glomerulosclerosis
Permeability Factor in Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS) is a renal syndrome characterized by proteinuria (usually nephrotic range), limited response to conventional therapy, and a poor renal prognosis, with progression to end stage renal…
- Trial name
- NCT00007475
- Testing
- Plasma exchange, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Focal Segmental Glomerulosclerosis
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
- Trial name
- DUPLEX (NCT03493685)
- Testing
- sparsentan, Irbesartan
- Where
- 226 sites in United States, Argentina and 20 more
- Volunteers
- 371 people
- Sponsor
- Travere Therapeutics, Inc.
Primary Focal Segmental Glomerulosclerosis
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional…
- Trial name
- NCT01573533
- Testing
- Rituximab
- Where
- 4 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Treatment Resistant Nephrotic Syndrome
Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)
This study will examine the safety and effectiveness of ACTHAR Gel, when used to treat 15 patients diagnosed with "treatment resistant nephrotic syndrome." Nephrotic syndrome is a group of symptoms that includes low levels of…
- Trial name
- NCT01129284
- Testing
- ACTHAR gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Proteinuric Kidney Disease, Diabetic Nephropathy
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to conventional ARB therapy (35-45% over 9 months).
- Conditions
- Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy
- Trial name
- NCT01129557
- Testing
- Aliskiren, Valsartan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Columbia University
Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
Focal Segmental Glomerulosclerosis (FSGS) is a devastating kidney disease which is difficult to treat and carries a poor prognosis, with 50% of affected children progressing to end stage renal disease (ESRD).
- Trial name
- NCT01113385
- Testing
- D-Galactose
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Children's National Research Institute
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
The purpose of this study was to assess the efficacy of the bleselumab regimen (basiliximab induction, tacrolimus, steroids and bleselumab) compared with the Standard of Care (SOC) regimen (basiliximab induction, tacrolimus…
- Trial name
- NCT02921789
- Testing
- Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF)
- Where
- 23 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Focal Segmental Glomerulosclerosis
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
This project will test whether adalimumab,and/or galactose can safely reduce proteinuria (abnormal amounts of protein in the urine) and protect kidney function better than standard treatment for patients with focal segmental…
- Trial name
- FONTII (NCT00814255)
- Testing
- Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
- Where
- 18 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- NYU Langone Health